SCHEMBL2318949

SCHEMBL2318949

CC[C@H](NC)C(=O)Nc1ccc(-c2ccc(F)cc2)n(CC(=O)NC2CCCc3ccccc32)c1=O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
XIAP P98170 2/20 0.56
TSHR P16473 2/20 0.44
HPGD P15428 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
DHODH Q02127 1/20 0.44
KMT2A Q03164 4/20 0.43
GPR139 Q6DWJ6 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
TAOK3 Q9H2K8 1/20 0.42
MEN1 O00255 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2318958 1.00 XIAP (0.56) XIAPTSHRHPGDL3MBTL1DHODH
SCHEMBL2318384 0.91 XIAP (0.65) XIAPTSHRHPGDDHODHKMT2A
SCHEMBL2318389 0.91 XIAP (0.65) XIAPTSHRHPGDDHODHKMT2A
SCHEMBL2319791 0.86 XIAP (0.67) XIAPTSHRHPGDL3MBTL1KMT2A
SCHEMBL2319796 0.86 XIAP (0.67) XIAPTSHRHPGDL3MBTL1KMT2A
SCHEMBL2319278 0.84 XIAP (0.40) XIAPKMT2AALDH1A1MEN1
SCHEMBL2319283 0.84 XIAP (0.40) XIAPKMT2AALDH1A1MEN1
SCHEMBL2319275 0.84 XIAP (0.40) XIAPKMT2AALDH1A1MEN1
SCHEMBL2316842 0.83 XIAP (0.45) XIAPTSHRDHODHKMT2ANPSR1
SCHEMBL2316836 0.83 XIAP (0.45) XIAPTSHRDHODHKMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989441-B2 Organic compounds NOVARTIS AG (CH) 2011-08-02 US claimed
US-20090069294-A1 Organic Compounds NOVARTIS AG (CH) 2009-03-12 US claimed
US-20110281845-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-11-17 US disclosed
US-20110281845-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-11-17 US disclosed
US-7989441-B2 Organic compounds NOVARTIS AG (CH) 2011-08-02 US disclosed
US-7989441-B2 Organic compounds NOVARTIS AG (CH) 2011-08-02 US disclosed
US-20090069294-A1 Organic Compounds NOVARTIS AG (CH) 2009-03-12 US disclosed
US-20090069294-A1 Organic Compounds NOVARTIS AG (CH) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069294-A1 Organic Compounds XIAP, BAX, MCL1 XIAP 1/4885TSHR 4844/4885HPGD 2185/4885
US-20110281845-A1 ORGANIC COMPOUNDS XIAP, BAX, MCL1 XIAP 1/4885TSHR 4844/4885HPGD 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.